Regional versus Extended Lymph Node Dissection for

Intrahepatic Cholangiocarcinoma: a randomized controlled trial

protocol

Li Qi,^{1*} Feng Yangyang,^{2*} Jin Yun,¹Xi Longfu,¹ Yu Yuanquan,¹ Guo Yinghao,¹ Zhang Xiaoxiao,¹Wu Di,¹ Li Jiangtao^{1#}

ABSTRACT

Introduction The mainstay treatment for intrahepatic cholangiocarcinoma is surgical resection, the impact of lymph node dissection and the scope of lymph node dissection for intrahepatic cholangiocarcinoma surgery is controversial. However, research on the comparative of regional lymphadenectomy and extended lymphadenectomy is still limited. This study will explore the effect of regional lymphadenectomy and extended lymphadenectomy in intrahepatic cholangiocarcinoma surgery patients to provide reliable evidence for further standardize the scope of lymph node dissection for intrahepatic cholangiocarcinoma surgery.

Methods and analysis This is a prospective, multicentre, randomised controlled trial in intrahepatic cholangiocarcinoma surgery patients. A total of 174 patients will be enrolled at the first clinic visit in sites from China. Participants will be allocated randomly to the regional lymphadenectomy group and extended lymphadenectomy group (1:1 ratio). Patients in different groups undergo the corresponding surgery. Primary study outcome is disease-free survival (DFS). Secondary study outcomes include incidence of severe Clavien–Dindo complications (\geq II), safety of operation, overall survival (OS), three-year survival rate, five-year survival rate and median mortality. Participants will be followed up at baseline, post-operation, every 3 months for the first 2 years and 6 months for the next 3 years to evaluate the impact of different surgery types. The analysis will be done according to protocol cohorts, adjusted by variables associated with intrahepatic cholangiocarcinoma.

Ethics and dissemination This study was approved by the ethical review committee of the second affiliated hospital Zhejiang University school of medicine (2019-261) and will provide reference for standardize the scope of lymph node dissection for intrahepatic cholangiocarcinoma surgery.

Trial registration: ClinicalTrials.gov, NCT04078230. Registered on September 6, 2019. The study is expected to last for more than five years, and the first patient was enrolled on August 22, 2020, and a total of 17 patients have been enrolled so far.

BACKGROUND

Intrahepatic cholangiocarcinoma (ICC) represents 10-15% of liver cancers which is

the second most common liver cancer.^[1] The incidence of ICC has increased worldwide over the past few decades, some studies suggest a possible link to viral hepatitis, metabolic syndrome and chemical contact.^[2-6] Under this trend, there is increasing interest in the standardized treatment of intrahepatic cholangiocarcinoma.

Surgical resection is the only effective treatment for ICC, but the postoperative recurrence rate is high, the median disease-free survival (DFS) is only 20 months, and the 5-year survival rate is about 14-30%. It is a malignant tumor with a poor prognosis. ^[7,8] Pathological classification, tumor size and number, lymph node metastasis (LNM) and other factors may be related to the poor prognosis of ICC.^[9-14] Several studies have

Strengths and limitations of this study

A major advantage of this trial is that its multicenter, large sample, randomized controlled design will yield reliable results regarding the intervention.

Patients from multiple regions made the study results broadly representative.

The surgeon will inevitably know the procedure that the patient undergoes, and although we exclude the surgeon from the experimental process outside of the operation, it may still have an impact on the results of the experiment.

shown that lymph node metastasis is a major risk factor for poor prognosis.^[10,12,15]

In previous studies, lymph node metastasis was presumed an intermediary step in dissemination to distant sites.^[16,17] But with the deepening of research, new results show that lymph node metastasis plays a more important and complex role in tumor development and metastasis. Primary tumors elicit anti-tumor immune responses by presenting antigens to lymph nodes, which may play an important role in tumor immunotherapy.^[18-21] A study in 2022 subversively proposed that lymph node metastases can resist T cell-mediated cytotoxicity induce tumor-specific immune tolerance and lead to distant tumor metastasis.^[22]

Different opinions on the role of lymph node metastasis in the progression and metastasis of intrahepatic cholangiocarcinoma have triggered controversy on the scope of lymph node dissection during radical resection of cholangiocarcinoma. The American Joint Committee on Cancer (AJCC) 8th edition indicates that radical resection of cholangiocarcinoma should remove at least 6 lymph nodes.^[23] American Hepato-Pancreato-Biliary Association (AHPBA) expert consensus statement suggested that the hepatoduodenal ligament, hepatic artery and retropancreatic lymph nodes should be dissected for ICC originating from the right hemiliver; the hepatoduodenal ligament, hepatic artery lymph nodes around the cardiac portion of the stomach and along the lesser curvature should be dissected for ICC originating from the left hemiliver.^[24] NCCN Guideline (V 2.2022) only support a regional lymphadenectomy dissection of the porta hepatis lymph nodes. Other studies proposed to group the lymph nodes according to the tumor location and expand the scope of lymph node dissection. For the right lobe tumor: Group 1 included lymph

nodes in the hepatoduodenal ligament; Group 2 included left gastric artery, common hepatic artery, coeliac artery and posterior surface of the pancreas head lymph nodes; Group 3 are distant nodes. Lymph nodes in the right cardial region and along the

Site/	Incidence	Five-year	DFS	OS	Recurrence	LNM rate	Main		
country		survival rate	(months)	(months)	rate		Etiology		
Global	6/100000	14-30%	20	30	40-80%	17-39.1%	HBV		
China	7.55/100000	9%~20%	19.3	26.1	70%	45-62%	HBV		

Table1	ICC epidemiology in the study sites ^[15,23,26-36]
--------	--

ICC, Intrahepatic cholangiocarcinoma; DFS, Disease-free survival; OS, Overall survival; LNM, Lymph node metastasis;

lesser curvature of the stomach are added to group 1 when the tumor is located in the left lobe.^[25]

Extended lymphadenectomy can obtain more lymph nodes and improve the accuracy of staging. However, whether this operation can inhibit tumor metastasis and recurrence, prolong the survival time and improve the quality of life of patients is still unclear. Therefore, we will design a multicenter randomized controlled study to assess the effect of extended lymph node dissection on patient prognosis and surgical safety.

The objectives of this trial are: (1) To evaluate whether extended lymph node dissection can improve the prognosis of patients undergoing radical cholangiocarcinoma; (2) To evaluate the safety and reliability of extended lymph node dissection; (3) To evaluate whether extended lymph node dissection can improve the accuracy of staging of intrahepatic cholangiocarcinoma.(4) To standardize the scope of lymph node dissection in radical resection of intrahepatic cholangiocarcinoma.

METHODS

This is a prospective, multicentre, randomized controlled trial in intrahepatic cholangiocarcinoma surgery patients. The study will be conducted and reported in accordance with Consolidated Standards of Reporting Trials guidelines.^[37]

Study settings

The trial will be conducted in China where incidence of intrahepatic cholangiocarcinoma was 7.55 per 100 000 population.^[23,32,38] The epidemiological indicators of intrahepatic cholangiocarcinoma in the study site are shown in Table 1. The selected experimental sites have a large geographical span and cover areas with different medical levels (the sites include cities located in the north, south, east, west of China and developed cities and developing cities).

Study population

All patients with intrahepatic cholangiocarcinoma who visited designated medical institutions during the study period will be screened to participate in the trial. The

detailed information of the enrolled patients was recorded as shown in Table 2.

The inclusion criteria were: 1) Permanent residents over age 18 in the study area. 2) The preoperative diagnosis was resectable intrahepatic cholangiocarcinoma. 3) The patient has independent ability, can understand and voluntarily sign the informed

study participants	
Experimental group Cont	rol
General Condition	
Age	
Gender (male: female)	
Nationality	
Place of birth	
Height	
BMI (kg/m²)	
Respiratory function	
Child-Pugh	
CONUT	
ASA	
ECOG	
Pathological Findings	
Pathological types	
Capsule integrity of tumor	
Nodule number,	
LNM	
MVI	
Laboratory Examinations	
HBV	
HCV	
Tumor marker	
Routine blood assay	
Liver function test	
Renal function	
Coagulation function	
Liver fibrosis	
Typing and Staging	
WHO typing	
AJCC typing	
AJCC staging	
Yamamoto staging	

Table 2 Demographic and clinical characteristics of the

BMI, Body Mass Index; CONUT, Controlling Nutritional Status; ASA, American Society of Anesthesiologists; ECOG, East Cooperative Oncology Group; LNM, Lymph node metastasis; MVI, Microvascular invasion; HBV, Hepatitis B Virus ;HCV, Hepatitis C Virus ;WHO, World Health

Organization ;AJCC, American Joint Committee on Cancer.

consent form, and can complete the follow-up plan.

The exclusion criteria were:1) The postoperative diagnosis was not intrahepatic cholangiocarcinoma. 2) The patient failed to perform the operation as planned. 3) An unplanned disease or treatment that occurs to a patient. 4) Other situations that not suitable for continuing to participate in the trial. 5) The patient voluntarily withdrew from the trial.

Informed consent

Patients participating in the experiments will all be given details of the study design and knowledge about intrahepatic cholangiocarcinoma. Patients were asked to sign an informed consent form at each stage of the study.

The trial's informed consent is available as online supplemental material 1.

Recruitment and randomisation

After fully understanding the experimental details and signing an informed consent form, the cholangiocarcinoma patients will be given a study number and enrolled into one of the study groups according to the randomization table: (1) Regional lymph node dissection group or (2) Extended lymph node dissection group. In the study, the research subjects were distinguished by the site code + number. Patients participating in the study were divided into two groups in a 1:1 ratio by the study coordinator according to a randomization table.

Figure 1 displays the study design.

Blinding

All participants except patients, the study coordinator and the operative staff were kept blind throughout the study, and the operative staff did not participate in other aspects of the study. Unblinding is only envisaged in case of a medical emergency (in such case, the investigator on site will have to justify to the Data Safety Monitoring Board (DSMB) the need for unblinding).

Interventions

regional lymph node dissection group

Hepatectomy + regional lymph node dissection (the 12th group lymph nodes). Surgical procedures: 1. Perform liver segment, hepatic lobe, hemi-hepatic or hepatic trilobe surgery according to the location of the primary tumor; 2. Skeletonization of the hepatoduodenal ligament; 3. The 12th group lymph nodes lymph nodes dissection. extended lymph node dissection group

Hepatectomy + extended lymph node dissection (the 8th,12th and 13th group lymph nodes for the right lobe tumor; the 1st, 3rd,7th,8th and 12th lymph nodes for the left lobe tumor).

Surgical procedures: 1. Perform liver segment, hepatic lobe, hemi-hepatic or hepatic trilobe surgery according to the location of the primary tumor; 2. Skeletonization of the hepatoduodenal ligament; 3. The 8th,12th and 13th group lymph nodes dissection for the right lobe tumor; the 1st, 3rd,7th,8th and 12th lymph nodes for the left lobe tumor.

Study outcomes

The primary outcome of the trial is disease-free survival (DFS). Secondary study

outcomes include incidence of severe Clavien–Dindo complications (\geq II), safety of operation, overall survival (OS), three-year survival rate, five-year survival rate, median mortality. tumor marker levels, liver function levels, blood routine levels, renal function levels.

Sample size

Based on previous studies, we set the five-year survival rate after surgery for intrahepatic cholangiocarcinoma to be 15%, set bilateral α =0.05, β =0.2, power=1- β =0.8. The ratio of the number of cases in the two groups was 1:1. Calculated by PASS11, the required minimum sample size was 78 cases, with a total of 156 cases in the two groups.

The loses visit rate was set at 10%, and the minimum sample size of this study was 174 cases.

Follow-up and measurements of outcomes

All information in the study will be recorded in the study specific Case Report Form (CRFs), the follow-up plan is shown in Table 3.

Physical and clinical examination at enrolment

The physical examination of the ICC patients will include the following assessments: age, gender, nationality, place of birth, height, body mass index (BMI), medical history, respiratory function, Child-Pugh score, Controlling Nutritional Status(COUNT) score, American Society of Anesthesiologist(ASA) score, Eastern Cooperative Oncology Group(ECOG) score. Magnetic resonance imaging will be performed to confirm the diagnosis of intrahepatic cholangiocarcinoma and to evaluate the feasibility of surgical resection.

baseline biological samples

At enrolment, a blood sample will be collected for analysis of HAV, HBV, HCV, HEV, tumor marker, routine blood assay, liver function test, renal function, coagulation function, Cirrhosis.

follow-up and household visits

The patient will undergo a thorough examination and evaluation within 1 week of diagnosis. Participants will follow guidelines for intervention and are asked to report any discomfort to their physician. The patient will sign the informed consent before surgery and record the patient's examination results. Blood routine examination, liver and kidney function and coagulation function were performed on the first postoperative day, and then every 3 days until discharge. Imaging examination was performed one week after operation to evaluate the recovery and complications. Patients are revisited every 3 months for the first 2 years after discharge and every 6 months thereafter until 5 years or death. Follow-up examination should include imaging examination, blood routine examination, tumor markers, and liver and kidney function, so as to assess the recurrence and progression of the tumor. If there is clinical suspicion of recurrence but no imaging evidence, further examination should be performed. Postoperative adjuvant therapy was performed according to the guidelines. Patients who cannot come to the hospital will be followed up by telephone and Electronic address.

Laboratory tests

hepatitis virus detection

Peripheral blood HBsAg, HBsAb, HBeAg, HBeAb, HBcAb and HCVAb were detected with the corresponding ELISA kit according to the instructions on the first day of admission.

tumor marker detection

Tumor markers such as AFP, CA199 and CEA were detected by ELISA with corresponding kits before operation and at each follow-up.

routine blood detection

Peripheral blood was collected before operation, every 3 days after operation and during follow-up. After anticoagulation, routine blood test was performed by Hematology Analyzer.

blood biochemical examination

The liver and kidney function and coagulation function were measured before operation, every three days after operation and during follow-up.

liver fibrosis

Before operation, venous blood was collected and serum was isolated to detect the levels of hyaluronic acid(HA), laminin(LN), Procollagen peptide Type 3(PIIINP) and Collage Type IV(C-IV) in serum.

Data management

Data collection was performed at each visit using a paper CRF form customized for the experiment, and the quality of study source documents and CRFs recorded data will be monitored by Clinical monitors following Good Clinical Practices. Data will be double-entered into the study database using OpenClinica open source software (V.3.14) for clinical data management at each study site. An automatic quality check is performed

Table 3 Schedule of enrolment, intervention	s and patient assessm	ents																			
Study period	Pre-enrolment	Allocation	Pre-operation	Operation	Post-operation	Hospital discharge							Follow	v up (mo	onths)						Unscheduled visits
Timepoint	-7 days	-7 days	-7 days	0 days	+3 days	+7-14 days	3	6	9	12	15	18	21	24	30	36	42	48	54	60	
Screening and enrolment																					
Eligibility screen	×																				
Informed consent	×																				
Randomisation		×																			
Interventions :																					
Hepatectomy + (R/E) LND				×																	
Patient assessments :																					
Demographics, medical history	×																				
Socioeconomic characteristics		×																			
Record of concomitant medication			×		×		×	×	×	×	×	×	×	×	×	×	×	×	×	×	x
Record of adverse events				×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
Physical/clinical examination	×		×		×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	x
Imaging examination	×		Δ		Δ	Δ	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
Temperature	×		×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
Blood pressure	×		×	×		×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
Weight	×		×		×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
Height	×						×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
MUAC	×						×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
Surgical safety assessment:																					
Operative time (mins)				×																	
Blood loss (ml)				×																	
Intraoperative blood transfusion volume				×																	
Hepatic portal occlusion				×																	
Vascular/bile duct anastomosis				×																	
Bile leak					×		×														V
Clavien-Dindo score					×		×														V
Postoperative exhaust time(hours)	llastad at the someone				×	×															

 \times indicates that the corresponding data is collected at the corresponding time point.

A Decide whether to perform the examination according to the patient's condition

(R/E) LND, (Regional/Extended) Lymph Node Dissection; MUAC, mid upper arm circumference.

BOX 1 Study outcomes							
Primary endpoint							
The disease-free survival of patients after surgery (Time							
interval from the date of operation to tumor progression) .							
Secondary endpoints							
Safety of operation.							
Incidence of severe Clavien–Dindo complications (≥II).							
Frequency and severity of adverse events.							
Three-year survival rate.							
Five-year survival rate.							
Overall survival.							
Median mortality.							

to ensure CRF integrity. The database system will automatically encrypt sensitive data to ensure data security and integrity, and include functions such as authorization, authentication and audit. Accompanying drugs registered in the database will be coded using the WHO Drug Reference List. This list uses the Therapeutic Chemical Classification System. History/current Medical conditions and adverse events will be coded using The Medical Dictionary for Regulatory Activities (MedDRA).

Analysis plan

The following analysis objectives have been identified: (A) Surgical effectiveness: This data compares disease-free survival, overall survival, 3-year survival, and 5-year survival in the two cohorts to compare the effectiveness of the two surgical methods for intrahepatic cholangiocarcinoma. (B) Surgical safety: The data were used to compare the operation time, intraoperative blood loss, intraoperative blood transfusion volume, whether to block the hepatic portal and the number and time of blocking, whether to perform vascular resection and anastomosis and the mode and time of anastomosis, the scope and number of lymph node dissection, the mode and time of biliary intestinal anastomosis, and the number of biliary fistula, and postoperative exhaust time between the two cohorts to compare the safety of the two surgical methods. (C) Tumor staging: This data compares the number of lymph node dissection procedures to determine whether expanded lymph node dissection contributes to accurate tumor staging.

Patient and public involvement

Patients will not be directly involved in the research process, but each institution will have staff to maintain communication with patients to ensure that their reasonable demands are met. At the same time, research institutions should establish research committees and maintain communication to ensure the reliability, consistency and safety of the research.

Ethics and dissemination

This study was approved by the the ethical review committee of the second affiliated hospital Zhejiang University school of medicine (2019-261). Trial results will be submitted to a peer-reviewed journal for publication within 1 year of study completion. The original project data will be published on the project website. No personal information about study participants will be released at any stage of the study.

DISCUSSION

Intrahepatic cholangiocarcinoma is a malignant liver tumor with an incidence second

only to hepatocellular carcinoma, and surgical resection is currently recognized as an effective treatment for intrahepatic cholangiocarcinoma.^[39]

Studies have found that compared with hepatocellular carcinoma, intrahepatic cholangiocarcinoma is more prone to lymph node metastasis, and multiple studies have found that lymph node metastasis is an independent risk factor affecting the prognosis of intrahepatic cholangiocarcinoma.^[40-43] Some studies have also pointed out that lymph node metastasis of intrahepatic cholangiocarcinoma is an intermediate step in distant metastasis. A study of intrahepatic cholangiocarcinoma reported that intrahepatic cholangiocarcinoma may have skip metastasis, half of the patients had direct second-stop lymph node metastasis.^[44] Based on the above research inferences, thorough lymph node dissection is helpful for accurate staging of intrahepatic cholangiocarcinoma and is beneficial to prevent distant metastasis of the seed tumor. These conjectures were also confirmed in subsequent studies.^[2] Therefore, lymph node dissection during radical resection of intrahepatic cholangiocarcinoma has become the consensus of major guidelines.

However, the scope of lymph node dissection is still controversial in different guidelines and studies. ^[15] Some studies have suggested that extended lymph node dissection can prolong the operation time, increase the intraoperative risk and may increase the incidence of serious complications such as biliary fistula, and has no significant effect on improving the prognosis of patients. ^[45,46] Other studies have found that expanded lymph node dissection can help to completely remove the tumor, prevent tumor recurrence, accurately judge tumor staging, and guide postoperative adjuvant therapy. It is beneficial to prolong the patient's survival time and improve the quality of life. ^[24,27,47-49]

At present, the studies on the comparison between regional lymph node dissection and expanded lymph node dissection in patients with intrahepatic cholangiocarcinoma are mostly retrospective small-sample studies with a long history (> 10 years). In recent years, the innovation of laparoscopic technology, robotic technology and other surgical techniques have shortened the operation time, improved the quality of surgery and reduced the surgical injury. Therefore, under the current background, it is necessary to carry out a multicenter, prospective, large-sample randomized controlled study to compare the efficacy of regional lymph node dissection and expanded lymph node dissection for intrahepatic cholangiocarcinoma.

In conclusion, in order to provide a reliable basis for standardizing the extent of lymph node dissection during radical resection of intrahepatic cholangiocarcinoma, we will implement a multicenter prospective randomized controlled study. To compare the efficacy of regional lymph node dissection and extended lymph node dissection in patients undergoing radical resection for intrahepatic cholangiocarcinoma, and to compare the safety and prognostic effects of the two procedures.

Author affiliations

1, Department of Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China

2, Department of General Surgery, The Third People's Hospital of Hangzhou, Hangzhou, Zhejiang, 310006, China

Contributors LQ and FY are joint first authors. Conceived and designed the study: LQ and LJT. Gave inputs to protocol methodology: LQ, FY, XL, JY, YY, GY, ZX and LJ. Wrote the first draft of the manuscript: LQ and FY. Wrote sections on sample size, data management and analysis plan: LQ, XL and JY. Wrote, reviewed and approved the manuscript: all authors.

Funding This study was supported by grants from The Second Affiliated Hospital of Zhejiang University Medical College (RCT-2019-018B).

Disclaimer The project funders do not have any role on study design, data collection and analysis.

Ethical approval: This study was approved by the ethical review committee of the second affiliated hospital Zhejiang University school of medicine (2019-261) **Competing interests** None declared.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic,

perihilar, and distal tumors. Ann Surg 1996;224(4):463-73; discussion 73-5.

2. Ruzzenente A, Conci S, Vigano L, et al. Role of Lymph Node Dissection in Small (</= 3 cm)

Intrahepatic Cholangiocarcinoma. J Gastrointest Surg 2019;23(6):1122-29.

3. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver

cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol

2012;57(1):69-76

4. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? *J Hepatol* 2004;**40**(3):472-7.

5. Kim SH, Han DH, Choi GH, et al. Oncologic Impact of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a Propensity Score-Matched Study. *J Gastrointest Surg* 2019;**23**(3):538-44.

6. Saha SK, Zhu AX, Fuchs CS, et al. Forty-Year Trends in Cholangiocarcinoma Incidence in

the U.S.: Intrahepatic Disease on the Rise. Oncologist 2016;21(5):594-9.

7. Yoh T, Cauchy F, Le Roy B, et al. Prognostic value of lymphadenectomy for long-term outcomes in node-negative intrahepatic cholangiocarcinoma: A multicenter study. *Surgery* 2019;**166**(6):975-82.

8. Squires MH, Cloyd JM, Dillhoff M, et al. Challenges of surgical management of intrahepatic cholangiocarcinoma. *Expert Rev Gastroenterol Hepatol* 2018;**12**(7):671-81.

9. Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. *JAMA Surg* 2014;**149**(6):565-74.

10. Ma CH, Hwang DW, Song KB, et al. Prognostic factors predicting survival rate over 10 years of patients with intrahepatic cholangiocarcinoma after hepatic resection. *Ann Surg Treat Res* 2020;**98**(3):116-23.

11. Ohta S, Morine Y, Imura S, et al. Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1alpha for Intrahepatic Cholangiocarcinoma. *Anticancer Res* 2019;**39**(11):6025-33.

12. Raoof M, Dumitra S, Ituarte PHG, et al. Development and Validation of a Prognostic Score for Intrahepatic Cholangiocarcinoma. *JAMA Surg* 2017;**152**(5):e170117.

13. Sahara K, Tsilimigras DI, Mehta R, et al. A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: The "metro-ticket" paradigm. *J Surg Oncol* 2019;**120**(2):223-30.

14. Spolverato G, Kim Y, Alexandrescu S, et al. Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical

Resection. Ann Surg Oncol 2016;23(1):235-43.

15. Hu H, Zhao H, Cai J. The role of lymph node dissection and a new N-staging system for intrahepatic cholangiocarcinoma: a study from the SEER database. *J Int Med Res* 2021;**49**(6):3000605211012209.

16. Brown M, Assen FP, Leithner A, et al. Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. *Science* 2018;**359**(6382):1408-11.

17. Pereira ER, Kedrin D, Seano G, et al. Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. *Science* 2018;**359**(6382):1403-07.

18. Binnewies M, Mujal AM, Pollack JL, et al. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4(+) T Cell Immunity. *Cell* 2019;**177**(3):556-71 e16.

19. Spitzer MH, Carmi Y, Reticker-Flynn NE, et al. Systemic Immunity Is Required for Effective Cancer Immunotherapy. *Cell* 2017;**168**(3):487-502 e15.

20. Wu TD, Madireddi S, de Almeida PE, et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. *Nature* 2020;**579**(7798):274-78.

21. Yost KE, Satpathy AT, Wells DK, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. *Nat Med* 2019;**25**(8):1251-59.

22. Reticker-Flynn NE, Zhang W, Belk JA, et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. *Cell* 2022;**185**(11):1924-42 e23.

23. Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates. *Chin Clin Oncol* 2018;**7**(5):52.

24. Weber SM, Ribero D, O'Reilly EM, et al. Intrahepatic cholangiocarcinoma: expert consensus statement. *HPB (Oxford)* 2015;**17**(8):669-80.

25. Shimada M, Yamashita Y, Aishima S, et al. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. *Br J Surg* 2001;**88**(11):1463-6.
26. Hu H, Xu G, Du S, et al. The role of lymph node dissection in intrahepatic cholangiocarcinoma: a multicenter retrospective study. *BMC Surg* 2021;**21**(1):359.

27. Cillo U, Fondevila C, Donadon M, et al. Surgery for cholangiocarcinoma. Liver Int 2019;39

Suppl 1:143-55.

28. Kambakamba P, Linecker M, Slankamenac K, et al. Lymph node dissection in resectable perihilar cholangiocarcinoma: a systematic review. *Am J Surg* 2015;**210**(4):694-701.

29. El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic Cholangiocarcinoma. *Surg Oncol Clin N Am* 2019;**28**(4):587-99.

30. Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. *Cancer Control* 2017;**24**(3):1073274817729245.

31. Tsilimigras DI, Sahara K, Paredes AZ, et al. Predicting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma. *J Gastrointest Surg* 2021;**25**(5):1156-63.

32. Doussot A, Gonen M, Wiggers JK, et al. Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. *J Am Coll Surg* 2016;**223**(3):493-505 e2.

33. Navarro JG, Lee JH, Kang I, et al. Prognostic significance of and risk prediction model for lymph node metastasis in resectable intrahepatic cholangiocarcinoma: do all require lymph node dissection? *HPB (Oxford)* 2020;**22**(10):1411-19.

34. Kubo S, Shinkawa H, Asaoka Y, et al. Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma. *Liver Cancer* 2022;**11**(4):290-314. 35. Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. *Gastroenterology* 2005;**128**(3):620-6.

36. Wirth TC, Vogel A. Surveillance in cholangiocellular carcinoma. *Best Pract Res Clin Gastroenterol* 2016;**30**(6):987-99.

37. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*2010;**340**:c332.

38. Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). *Nat Rev Gastroenterol Hepatol* 2016;**13**(5):261-80.

39. Wu W, He X, Andayani D, et al. Pattern of distant extrahepatic metastases in primary liver cancer: a SEER based study. *J Cancer* 2017;**8**(12):2312-18.

40. Lurje G, Bednarsch J, Czigany Z, et al. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma. *Eur J Surg Oncol* 2019;**45**(8):1468-78.

 Asaoka T, Kobayashi S, Hanaki T, et al. Clinical significance of preoperative CA19-9 and lymph node metastasis in intrahepatic cholangiocarcinoma. *Surg Today* 2020;**50**(10):1176-86.
 Harada N, Yoshizumi T, Yamashita YI, et al. Impact and Prediction of Lymph Node Involvement in Patients with Intrahepatic Cholangiocarcinoma After Curative Resection. *Anticancer Res* 2017;**37**(7):3763-69.

43. Ke Q, Wang L, Lin Z, et al. Prognostic Value of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma Patients With Clinically Negative Lymph Node Metastasis: A Multi-Center

Study From China. Front Oncol 2021;11:585808.

44. Nozaki Y, Yamamoto M, Ikai I, et al. Reconsideration of the lymph node metastasis pattern (N factor) from intrahepatic cholangiocarcinoma using the International Union Against Cancer TNM staging system for primary liver carcinoma. *Cancer* 1998;**83**(9):1923-9.

45. Reames BN, Ejaz A, Koerkamp BG, et al. Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: A multi-institutional analysis. *J Surg Oncol* 2017;**116**(2):133-39.

46. Zhou R, Lu D, Li W, et al. Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma? A systematic review and meta-analysis. *HPB (Oxford)* 2019;**21**(7):784-92.

47. Ma WJ, Wu ZR, Hu HJ, et al. Extended Lymphadenectomy Versus Regional Lymphadenectomy in Resectable Hilar Cholangiocarcinoma. *J Gastrointest Surg* 2020;**24**(7):1619-29.

48. Zhang XF, Xue F, Dong DH, et al. Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis. *Ann Surg* 2021;**274**(6):e1187-e95.

49. Kim SH, Han DH, Choi GH, et al. Extent of Lymph Node Dissection for Accurate Staging in Intrahepatic Cholangiocarcinoma. *J Gastrointest Surg* 2022;**26**(1):70-76.




Figure 1 ICC LND trial design. ICC, Intrahepatic cholangiocarcinoma; RLND, Regional Lymph Node Dissection; Extended Lymph Node Dissection